Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Merck & Co. (NYSE: MRK) | Delayed: 149.88 +1.58 (1.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.30 | 52 Week High | $65.46 | |||
| Open | $147.11 | 52 Week Low | $47.97 | |||
| Day High | $150.00 | P/E | 101.96 | |||
| Day Low | $147.11 | EPS | $1.47 | |||
| Volume | 9,007,883 | |||||
